New drug targets Hard-to-Treat tumors in early trial

NCT ID NCT05735366

Completed Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Mar 15, 2026 · Last updated May 13, 2026 · Updated 5 times

Summary

This early-phase study tested a new drug called SAIL66 in 22 adults with advanced solid tumors that have a specific protein (CLDN6). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. Participants received the drug by infusion, and researchers monitored side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Cancer Institute Hospital of JFCR

Tokyo, Koto Ku, 135-8550, Japan
Georgia Cancer Center at Augusta University

Augusta, Georgia, 30912, United States
MUSC Hollings Cancer Center

Charleston, South Carolina, 29425, United States
National Cancer Center Hospital

Tokyo, Chuo Ku, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan
Shizuoka Cancer Center

Shizuoka, Sunto-gun, 411-8777, Japan
Tennessee Oncology, PLLC

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR